Research and development relating to pharmaceutical products, subcontracting, advisory service;6.Education service and business service;7.Research service and investment business;8.Bioengineering and bio-pharmaceutical product research;9.Health and medical research;10.Joint research with domestic or international institutions;11.Technical research service for other domestic or international institutions;12.Plant design, purchasing agency, manufacture, construction, validation and supervision service;13.Real estate sale and purchase and leasing business;14.Transportation business;15.Parking lot business;16.Warehousing business;17.Businesses related to, necessary for, or incidental to any of the foregoing. Article 3 (Location of Head Office and Establishment of Branch, etc.) The Company shall have its head office in Incheon City and, if necessary, may establish branches, representative offices, business offices, sales offices, or local subsidiaries by a resolution of the Board of Directors (BOD) or of such a committee as authorized by the BOD. Article 4 (Method of Public Notices) The Company’s public notices shall be published in the Company’s website (http://samsungbiologics.com); provided, however, that in the event the public notices cannot be posted electronically due to computer system error or other unavoidable circumstances, the public notices shall be published in the JoongAng Ilbo, a daily newspaper of general circulation published in Seoul. Chapter 2.Shares Article 5 (Total Number of Shares Authorized to be Issued) The total number of shares that the Company is authorized to issue shall be Five Hundred Million (500,000,000) shares. Article 6 (Par Value per Share) The par value of each share to be issued by the Company shall be Two Thousand Five Hundred (2,500) won. Article 7 (Total Number of Shares to be Issued upon Incorporation) The total number of shares to be issued at the time of incorporation of the Company shall be One Million Five Hundred Thousand (1,500,000) shares. Article 8 (Classes of Shares and Share Certificates) ①The classes of shares to be issued by the Company shall be common shares and preferred shares, each of which shall be in registered form.②Preferred shares to be issued by the Company shall be preferred shares concerning dividends with non-voting rights, and the number of the preferred shares shall not be more than Fifty Million (50,000,000) shares.③Dividends on the preferred shares shall be first paid in cash at such dividend rate as determined by the BOD or such a committee as authorized by the BOD at the time of issuance based on the par value of the preferred shares.④In the event that the dividend rate of the common shares exceeds that of the preferred shares under Paragraph 3, any excess amount available for distribution after payment of dividends on the preferred shares and the common shares at the same ividend rate as that for the preferred shares shall be equally distributed to both common and preferred shareholders in proportion to their shareholding.⑤In the event that preferred dividends are not fully distributed on the preferred shares for any given fiscal year, any accumulated undistributed dividends shall be preferentially distributed first at the time of distribution of dividends in the immediately following fiscal year.⑥In case of rights issues, bonus issues or stock dividends, common shareholders shall be entitled to common shares, and preferred shareholders shall be entitled to preferred shares, in proportion to their respective shareholding; provided, however, that in case of rights issues, bonus issues or stock dividends, the Company may, if necessary, issue only one class of shares, where all the shareholders shall be entitled to such class of shares to be issued. Article 8-2(Electronic Registration of Rights to be Indicated on Shares and Stock Warrant Certificates) The Company shall electronically register rights to be indicated on shares and stock warrant c

Research- Development- And others Communication Communicate to - Client- Staff- Regulatory Agency- Audit committee- Others BCMO The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. Annual Operation Embedding BCMS is the ongoing cycle of activities of the business continuity management program, which builds organizational resilience, and is the professional practice that defines how to integrate business continuity awareness and practice into business as usual activities. Embedding BCMS Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an incident · Performing Risk and Threat Mitigation Measures Implementation - Implements the solutions agreed in the designed stage · Development of Tactical/Operational Business Continuity Strategy· Establishment of Business Continuity Plans & a response structure Validation - Confirms that the business continuity program meets the objectives set in the policy and the plans and procedures in place are effective. · Exercise Program: performing annual exercises with various types of scenario by each department as well as company-wide· Management Review to ensure it aligns with organizational objectives Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an inc

research on the harmful factors of musculoskeletal disorders and deliver a program for the prevention of musculoskeletal disorders to achieve a better working environment. Operation of Mental Health ClinicWe operate a variety of programs for mental health to prevent any mental health issues and mental health related accidents occurring for our valued employees. Industrial Hygiene Management Work Environment AssessmentWe continue to make the essential efforts to create healthy workplaces by measuring the exposure levels of harmful factors in the work environment in order to prevent any health problems and create a safe and pleasant working environment. Chemical Risk AssessmentWe assess the hazards of handling chemical substances and establish the relevant safety management measures to ensure that all our employees remain “chemically safe.” Hands-on Safety TrainingWe run hands-on training programs to enhance the safety and emergency response capabilities of all our employees.

research collaboration centered around ADC Toolbox co-development. Our investment in AimedBio holds significance because it is our first investment in a domestic biotech company with proprietary technology. Likewise, we plan to gain competitiveness in ADC business effectively through various investments in companies with advanced technologies, in addition to having our proprietary ADC conjugation facility.Biosimilar business on trackOur subsidiary, Samsung Bioepis is also expanding its business by focusing on pipeline development. With product sales steadily increasing due to higher prescription rate for existing products and new product launches, we also expanded coverage for Epysqli (a biosimilar product referencing Soliris, SB12), launched in the EU and for Hadlima (a biosimilar product referencing Humira, SB5), launched in the U.S last July. In addition, we released phase 3 clinical data for Stelara biosimilar (SB17), an autoimmune disease treatment, and entered into a commercialization agreement with one of the global biopharmaceutical companies named Sandoz. We will continue to develop and provide patients with high-quality biosimilar products with bioequivalence to the original products.Constant efforts to develop a more sustainable futureAs a leading company to promote sustainability management for the CDMO industry, Samsung Biologics is making constant efforts to contribute to a more sustainable future. As the company chairing the supply chain sector of the Sustainable Markets Initiative Health Systems Task Force, led by His Majesty King Charles III, we have published an Open Letter, co-signed by the members of SMI Healthcare Systems Task Force including AZ, GSK, and Sanofi. The letter outlines 8 actions urging suppliers to commit to the sustainability targets to achieve Net Zero in the bio-industry. This letter underscores our unwavering commitment to achieving Net Zero as soon as possible. In addition, we joined the Sustainable Aviation Buyers Alliance in September this year to promote investments in Sustainable Aviation Fuel (SAF) and offset carbon emissions in travel and logistics. Samsung Biologics will continue to nurture our core while developing and growing to meet the expectations of our shareholders. Your continued interest and support for our business is greatly appreciated. Thank you.October 25, 2023 President & CEO, Samsung Biologics John Rim

CEO MESSAGE Driven. For Life.SAMSUNG BIOLOGICS 2023. 04IR NewsletterDear Investors,This is John Rim, CEO of Samsung Biologics.I would like to begin by expressing my deep gratitude and appreciation for your continued interest and support in Samsung Biologics.Key HighlightsFinancial Performance (Consolidated)• Steady YoY Sales growth for 13 consecutive quarters since the outbreak of COVID 19 pandemic (Q1'20-Q1'23) CAGR at 52% (20~23)• Revenue: KRW 720.9B (YoY +41%) • Operating Profit: KRW 191.7B (YoY +9%)CMO/CDO• P5 investment in Bio Campus II announced (Mar.)• Strengthened Partnerships with Big Pharmas (CMO, CDO)• Won CDMO Leadership Awards in all 6 Categories (Feb.)• Cum. contract amount reached USD 9.9BBusiness Expansion• Opening of a regional sales office in New Jersey, US (Mar.)* Investment for ADC manufacturing facilities announced (Jan.)• Strategic investment in Araris Biotech via Life Science FundBioepis• Launching of Lucentis biosimilar (SB11) in GER, UK, CA (Mar.)• Positive CHMP Opinion received for Soliris biosimilar (SB12)• Upcoming US launching of Humira Biosimilar (SB5) (Compertitive edge gained by high & low-concentration, prefilled syringe and auto-injector, etc.)Samsung Biologics announced our first quarter financial results, and we are pleased to report quarterly financial performance with consolidated revenue of 720.9 billion won up by 41% YoY and an operating profit of 191.7 billion won up by 9% YoY. Since the beginning of the COVID19 pandemic, sales have increased year on year for 13 consecutive quarters, spurred by significant growth in the CMO business. Based on these solid financial results, we are revising our guidance for our annual revenue growth rate from 10-15%, which we announced this January, to 15%-20% for year 2023.Samsung Biologics has been operating its existing Plants 1 through 3 at full capacity while maximizing operational efficiency and maintaining steady and stable manufacturing output. As a result, we secured CMO contracts with global big pharmas including GSK, Pfizer, and Eli Lilly, to name a few, totaling roughly KRW 500 billion, bringing the total accumulated CMO contract amount to approximately USD 9.9 billion (KRW 13 trillion). We have also been able to enter into a partnership with a large pharmaceutical company in our CDO business and continued to build on our solid track record. Samsung Bioepis, a wholly owned subsidiary of ours since April 2022, has also contributed to our swift top-line growth by broadening revenue streams from the expansion of Lucentis biosimilar (SB11) sales in the United States, and other newly launched markets such as Germany, UK and Canada.Simultaneously, in line with the company's three-dimensional growth strategy, Samsung Biologics continues to augment our differentiated "Super Gap" CDMO competitive edge through expansions in our capacity, geographic presence, and business portfolio.Capacity Expansion | Announcement of investment in Bio Campus II, with the construction of Plant 5Plant 4 construction has been fully on track, with its 60,000L portion going operational in October last year, and the remaining 180,000L to go live in June of this year. We have already sealed a number of large-scale manufacturing contracts with Plant 4, signing 9 clients on 12 products, and are actively negotiating with 29 additional clients on 44 products.The robust demand seen for outsourced biopharmaceutical manufacturing convinced us that the time has come to proac- tively make this investment as part of our expansion strategy in order to further expand our global CMO market leadership. In this regard, we have decided to invest 1.98 trillion won ($1.51 billion) in the construction of our fifth facility in Bio Campus II, which will be located on a 96,000-square-meter plot. This new Plant 5, with a capacity of 180,000L, will break ground in the first half of this year and expected to complete co

Dear Investors, This is John Rim, CEO of Samsung Biologics. First and foremost, I would like to express my sincere gratitude and appreciation towards your continued interest and ongoing trust in Samsung Biologics over the past year. In 2022, Samsung Biologics achieved all of its annual targets in existing business divisions and successfully expanded its business scope for long-term, sustainable growth of the company. 2022 Financial Results (Consolidated) Cumulative revenue surpassed KRW 3T *the first and only company among Korean Pharma Revenue: KRW 3,001.3B (YoY +91%) *SBL(separated): KRW 2,437.3B Operating profit: KRW 983.6B (YoY +83%) CMO/CDO Plant 4 partial operations within 23 months of groundbreaking Launched "S-DUALTM and 'DEVELOPICKTM' * Bispecific antibody platform * Drug candidates developability platform Continued orders momentum: Cum. contract amount $9.5B Business Expansion Completion of KRW 3.2T rights offering (Apr.) Full acquisition of Samsung Bioepis (Apr.) Purchase of land for Biocampus II (Jul.) Investments in biotechs via Life Science Fund * Jaguar Gene Therapy (Mar.) and Senda Biosciences (Aug) Biosimilar Business US launch of Lucentis Biosimilar (SB11) (Jun.) FDA approval of high-conc. Humira Biosimilar (SB5) (Aug.) R&D expertise synergizing top-line growth of CDMO biz [A phenomenal fiscal year marked by unprecedented financial performance, with consolidated annual revenue exceeding KRW 3 trillion and an operating profit of around KRW 1 trillion, to be the first and only Korean pharma company to surpass KRW 3 trillion mark in annual sales] Significant and unpredictable volatility from macroeconomic and geopolitical factors has dominated the business environment in 2022. Interest rates were on an upward march, inflation was reaching what appeared at the time to be the generational highs, and exchange rates rose sharply. Despite such an unfavorable business environment, we were able to keep all three plants running at full capacity and maintain industry-leading batch success rates while minimizing product changeover (PCO) based on our operational excellence. As a result, for the first time in a half-year period, we surpassed KRW 1 trillion in revenue and have since broken our own record every quarter. In this regard, we are pleased to announce that we became the first and only Korean pharma company to surpass KRW 3 trillion mark in consolidated annual sales, with an operating profit of around KRW 1 trillion. [Plant 4, the world's largest plant, is on track to be completed within the first half of this year, with active presales activities rapidly locking in capacity.] Last October, Samsung Biologics began partial operations of Plant 4 (60,000 liters), the world's largest bio manufacturing site with a capacity of 240,000 liters, within 23 months after the groundbreaking, which was 6 months faster than the original 29-month timeline. It will be fully operational by the first half of this year, and presales activities have successfully locked in capacity. Prior to the plant's full ramp-up, we signed large-scale manufacturing contract agreements for 11 products with 8 global biopharmaceutical companies, and we are actively communicating with 26 other major clients on approximately 34 products. Based on our key competitive advantages of "speed" and "execution," we will strive to complete Plant 4 construction without a hitch and demonstrate our commitment to meeting client needs in a timely manner in order to solidify our trust-based partnership with our clients. [Taking the leap to become a fully integrated global biopharmaceutical company through active investments and portfolio diversification] In response to rising biopharmaceutical CMO demand, Samsung Biol